Briefly, it was demonstrated that i) CCL2 attracts macrophages in the tumor microenvironment, which ultimately favor cancer progression (35); ii) CCL2 is involved in the metastatic process in several cancers, being its neutralization with anti-CCL2 antibodies associated with a reduction of the metastatic ability (36); and iii) the blockade of CCL2/CCR2 axis produces therapeutic effects in a mouse model of hepatocellular carcinoma (37). This evidence concerns the gene CCR2 and cancer.